Compare ADMA Biologics Inc (ADMA) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.53. The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | GPTY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $50.52 |
52-Week Low | $7.60 | $34.73 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GPTY trades at $44.83, up 3.15% in the last 24 hours, with technical indicators showing a bearish trend but oversold RSI signals. The ETF maintains a consistent weekly dividend payout strategy, with recent distributions ranging from $0.30 to $0.38. News highlights focus on its AI and tech portfolio exposure and option-income strategy, though technical momentum remains weak.
Outlook is mixed: high dividend yield and AI theme appeal to income investors, but bearish technicals and reliance on semiconductor momentum pose risks. Investor sentiment is cautious amid volatile tech sector performance, requiring close monitoring of NAV stability and market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
